Vertex Pharmaceuticals

Vertex Pharmaceuticals

Yahoo Finance • 21 hours ago

Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead

Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy. Continue Reading... Full story

Yahoo Finance • 2 days ago

Vertex: Q3 Earnings Snapshot

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter profit of $653.6 million. On a per-share basis, the Boston-based company said it had net income of $2.56. Earnings, adjusted for one-time gain... Full story

Yahoo Finance • 2 days ago

Vertex raises 2026 revenue guidance following mixed Q3 results

[Third Quarter Q3 Profits Stock Trading Chart 3D Background] filo * Vertex Pharmaceuticals (VRTX [https://seekingalpha.com/symbol/VRTX]) slightly boosted its 2026 revenue guidance range after reporting Q3 financial results that beat on... Full story

Yahoo Finance • 2 days ago

Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance Hike

Vertex stock rose late Monday on better-than-expected third-quarter sales and a guidance boost following its Crinetics close. Continue Reading... Full story

Yahoo Finance • 2 days ago

Stock market today: Dow, S&P 500, Nasdaq futures recover from bruising sell-off ahead of busy week

US stock futures climbed in premarket trading on Monday as investors regained risk appetite ahead of another packed week of earnings, midterm elections, and a key jobs report. Futures on the Dow Jones Industrial Average (YM=F) rose 0.4%,... Full story

Yahoo Finance • 3 days ago

Vertex Pharmaceuticals Q3 2026 Earnings Preview

* Vertex Pharmaceuticals (VRTX [https://seekingalpha.com/symbol/VRTX]) is scheduled to announce Q3 earnings results on Monday, November 2, after market close. * The consensus EPS estimate is $4.75 [https://seekingalpha.com/symbol/VRTX/... Full story

Yahoo Finance • 3 days ago

Vertex Pharmaceuticals earnings: what to look for from VRTX

Vertex Pharmaceuticals earnings: what to look for from VRTX Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here's what to expect. Vertex Pharmaceuticals beat analy... Full story

Yahoo Finance • 4 days ago

Vertex Pharmaceuticals (VRTX) Stock May Still Have Value Following A 190% Run

Vertex Pharmaceuticals has delivered a strong multi year share price run, and the question now is whether that climb can be backed up by the cash the business is expected to generate. With a Discounted Cash Flow (DCF) framework available,... Full story

Yahoo Finance • 11 days ago

Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the k... Full story

Yahoo Finance • 12 days ago

How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading... Full story

Yahoo Finance • 12 days ago

How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading... Full story

Yahoo Finance • 13 days ago

Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project

VORTEX ENERGY CORP Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profiles VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vortex... Full story

Yahoo Finance • 17 days ago

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

The S&P 500 Health Care Sector Index (XLV) gained 3% for the week.The top S&P 500 healthcare gainers and losers for the past week are as follows:TOP FIVE GAINERS: * Idexx Laboratories (IDXX [https://seekingalpha.com/symbol/IDXX]) +8.18%... Full story

Yahoo Finance • 19 days ago

1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm

1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns,... Full story

Yahoo Finance • 20 days ago

Vortex Energy Corp. Announces Extension of Marketing Program

VORTEX ENERGY CORP VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce, further to its news release on July 24, 2026, th... Full story

Yahoo Finance • 21 days ago

3 Top Quality Value Stocks To Watch In October 2026

Rising gasoline and diesel costs are pushing US inflation higher, and that puts steady cash generation and conservative balance sheets back in the spotlight. When borrowing stays expensive and prices keep climbing, investors often pay clos... Full story

Yahoo Finance • 28 days ago

NVIDIA And 2 Elite Undervalued Stocks To Own

Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and sti... Full story

Yahoo Finance • last month

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen... Full story

Yahoo Finance • last month

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select... Full story

Yahoo Finance • last month

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

On September 22, Truist analyst Danielle Brill identified a "significant positive readthrough" for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The da... Full story